HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mechanisms of aspirin resistance.

Abstract
Aspirin is integral to the secondary prevention of cardiovascular disease and acts to impair the development of platelet-mediated atherothromboembolic events by irreversible inhibition of platelet cyclooxygenase-1 (COX-1). Inhibition of this enzyme prevents the synthesis of the potent pro-aggregatory prostanoid thromboxane A2. A large number of patients continue to experience atherothromboembolic events despite aspirin therapy, so-called 'aspirin treatment failure', and this is multifactorial in aetiology. Approximately 10% however do not respond appropriately to aspirin in a phenomenon known as 'aspirin resistance', which is defined by various laboratory techniques. In this review we discuss the reasons for aspirin resistance in a systematic manner, starting from prescription of the drug and ending at the level of the platelet. Poor medication adherence has been shown to be a cause of apparent aspirin resistance, and may in fact be the largest contributory factor. Also important is high platelet turnover due to underlying inflammatory processes, such as atherosclerosis and its complications, leading to faster regeneration of platelets, and hence of COX-1, at a rate that diminishes the efficacy of once daily dosing. Recent developments include the identification of platelet glycoprotein IIIa as a potential biomarker (as well as possible underlying mechanism) for aspirin resistance and the discovery of an anion efflux pump that expels intracellular aspirin from platelets. The absolute as well as relative contributions of such factors to the phenomenon of aspirin resistance are the subject of continuing research.
AuthorsChristopher N Floyd, Albert Ferro
JournalPharmacology & therapeutics (Pharmacol Ther) Vol. 141 Issue 1 Pg. 69-78 (Jan 2014) ISSN: 1879-016X [Electronic] England
PMID23993980 (Publication Type: Journal Article, Review)
Copyright© 2013.
Chemical References
  • Cyclooxygenase Inhibitors
  • Integrin beta3
  • Thromboxane A2
  • Cyclooxygenase 1
  • Aspirin
Topics
  • Aspirin (pharmacokinetics, pharmacology, therapeutic use)
  • Blood Platelets (drug effects, metabolism)
  • Cyclooxygenase 1 (drug effects, metabolism)
  • Cyclooxygenase Inhibitors (pharmacokinetics, pharmacology, therapeutic use)
  • Drug Interactions
  • Drug Resistance
  • Humans
  • Integrin beta3 (drug effects, metabolism)
  • Medication Adherence
  • Tachyphylaxis
  • Thromboembolism (drug therapy, prevention & control)
  • Thromboxane A2 (antagonists & inhibitors, metabolism)
  • Treatment Failure

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: